FDA accepts SCENESSE® clinical data package for NDA submission
17 July 2016 Clinuvel prepares New Drug Application (NDA) for the treatment...
Read More
FDA awards SCENESSE® Fast Track designation for treatment of EPP
05 July 2016 Executive summary: FDA awards Fast Track Designation¹ to expedite...
Read More
CLINUVEL’s SCENESSE® launched in Europe
20 June 2016 First commercial delivery, SCENESSE® approved as standard of care...
Read More
CLINUVEL added to Nasdaq International Designation
31 May 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...
Read More
SCENESSE® treatment in Europe
17 May 2016 German Porphyria Expert Centres to start distribution of SCENESSE®...
Read More
CLINUVEL Newsletter - April 2016
4 April 2016 Clinuvel is arriving at a point many of our...
Read More
NICE Highly Specialised Technology workshop reviews SCENESSE®
23 March 2016 NICE’s technical team invited stakeholders with an interest in...
Read More
s.708A Notice
18 March 2016 Notice under section 708A(5)(e) of the Corporations Act 2001...
Read More
Appendix 3B
18 March 2016 Enclosed is a new issue announcement, application for quotation...
Read More
CLINUVEL accredits first European EPP expert centres
13 March 2016 CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY)...
Read More